Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Division of Endocrinology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
J Clin Endocrinol Metab. 2023 Apr 13;108(5):e120-e128. doi: 10.1210/clinem/dgac670.
Pancreatogenic diabetes refers to diabetes mellitus (DM) that develops in the setting of a disease of the exocrine pancreas, including pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP). We sought to evaluate whether a blunted nutrient response of pancreatic polypeptide (PP) can differentiate these DM subtypes from type 2 DM (T2DM).
Subjects with new-onset DM (<3 years' duration) in the setting of PDAC (PDAC-DM, n = 28), CP (CP-DM, n = 38), or T2DM (n = 99) completed a standardized mixed meal tolerance test, then serum PP concentrations were subsequently measured at a central laboratory. Two-way comparisons of PP concentrations between groups were performed using Wilcoxon rank-sum test and analysis of covariance while adjusting for age, sex, and body mass index.
The fasting PP concentration was lower in both the PDAC-DM and CP-DM groups than in the T2DM group (P = 0.03 and <0.01, respectively). The fold change in PP at 15 minutes following meal stimulation was significantly lower in the PDAC-DM (median, 1.869) and CP-DM (1.813) groups compared with T2DM (3.283; P < 0.01 for both comparisons). The area under the curve of PP concentration was significantly lower in both the PDAC-DM and CP-DM groups than in T2DM regardless of the interval used for calculation and remained significant after adjustments.
Fasting PP concentrations and the response to meal stimulation are reduced in new-onset DM associated with PDAC or CP compared with T2DM. These findings support further investigations into the use of PP concentrations to characterize pancreatogenic DM and to understand the pathophysiological role in exocrine pancreatic diseases (NCT03460769).
胰源性糖尿病是指在胰腺外分泌疾病(包括胰腺导管腺癌 [PDAC] 和慢性胰腺炎 [CP])背景下发生的糖尿病。我们旨在评估胰腺多肽(PP)的营养反应迟钝是否能够区分这些 DM 亚型与 2 型糖尿病(T2DM)。
在 PDAC(PDAC-DM,n=28)、CP(CP-DM,n=38)或 T2DM(n=99)新诊断的 DM(发病<3 年)患者中完成标准化混合餐耐量试验,然后在中央实验室测量血清 PP 浓度。使用 Wilcoxon 秩和检验和协方差分析比较组间 PP 浓度的双向比较,同时调整年龄、性别和体重指数。
PDAC-DM 和 CP-DM 组的空腹 PP 浓度均低于 T2DM 组(P=0.03 和<0.01)。餐后 15 分钟 PP 的变化倍数在 PDAC-DM(中位数,1.869)和 CP-DM(1.813)组明显低于 T2DM(3.283;两者均<0.01)。无论计算间隔如何,PDAC-DM 和 CP-DM 组的 PP 浓度曲线下面积均明显低于 T2DM,调整后仍有统计学意义。
与 T2DM 相比,与 PDAC 或 CP 相关的新发 DM 患者的空腹 PP 浓度和对餐刺激的反应降低。这些发现支持进一步研究使用 PP 浓度来描述胰源性糖尿病并了解外分泌胰腺疾病的病理生理作用(NCT03460769)。